## **Tobias Boettler**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2967121/publications.pdf Version: 2024-02-01



TORIAS ROFTTLED

#	Article	IF	CITATIONS
1	Hepatitis E virus and Bell's palsy. European Journal of Neurology, 2022, 29, 820-825.	1.7	7
2	Immune-mediated Hepatitis associated with SARS-CoV-2 mRNA vaccination. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	1
3	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection. JHEP Reports, 2022, 4, 100480.	2.6	6
4	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 397-409.	1.8	59
5	SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Journal of Hepatology, 2022, 77, 653-659.	1.8	67
6	SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals. Nature Microbiology, 2022, 7, 675-679.	5.9	29
7	Mechanisms of CD8+ T-cell failure in chronic hepatitis E virus infection. Journal of Hepatology, 2022, 77, 978-990.	1.8	15
8	TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. Gut, 2021, 70, 1550-1560.	6.1	46
9	Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1-12.	2.3	22
10	Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nature Medicine, 2021, 27, 78-85.	15.2	295
11	IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. Journal of Hepatology, 2021, 74, 649-660.	1.8	20
12	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections. Clinical Gastroenterology and Hepatology, 2021, 19, 195-198.e2.	2.4	12
13	Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection. Nature Immunology, 2021, 22, 229-239.	7.0	95
14	Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature, 2021, 592, 444-449.	13.7	233
15	Blood reelin in the progression of chronic liver disease. Advances in Medical Sciences, 2021, 66, 148-154.	0.9	4
16	Acute CNS infections – Expanding the spectrum of neurological manifestations of hepatitis E virus?. Journal of the Neurological Sciences, 2021, 423, 117387.	0.3	7
17	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. Journal of Hepatology, 2021, 74, 1362-1372.	1.8	74
18	Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity, 2021, 54, 1594-1610.e11.	6.6	210

TOBIAS BOETTLER

#	Article	IF	CITATIONS
19	Reply to: "lgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?― Journal of Hepatology, 2021, 75, 231-232.	1.8	0
20	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature, 2021, 597, 268-273.	13.7	279
21	Reply to: "Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?― Journal of Hepatology, 2021, 75, 489-490.	1.8	3
22	Hepatitis E virus as a trigger for Guillain-Barré syndrome. BMC Neurology, 2021, 21, 304.	0.8	5
23	Th1-Biased Hepatitis C Virus-Specific Follicular T Helper-Like Cells Effectively Support B Cells After Antiviral Therapy. Frontiers in Immunology, 2021, 12, 742061.	2.2	2
24	Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination. Nature Communications, 2021, 12, 6720.	5.8	33
25	Plasma Cyclic Guanosine Monophosphate Is a Promising Biomarker of Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. Frontiers in Medicine, 2021, 8, 803119.	1.2	1
26	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Reports, 2020, 2, 100169.	2.6	120
27	Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. Basic Research in Cardiology, 2020, 115, 78.	2.5	37
28	Exhausted phenotype of follicular CD8 T cells in CVID. Journal of Allergy and Clinical Immunology, 2020, 146, 912-915.e13.	1.5	17
29	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports, 2020, 2, 100113.	2.6	378
30	Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination. Journal of Clinical Investigation, 2020, 130, 998-1009.	3.9	39
31	Disentangling molecular mechanisms regulating sensitization of interferon alpha signal transduction. Molecular Systems Biology, 2020, 16, e8955.	3.2	41
32	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	6.1	100
33	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	3.7	58
34	HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. Scientific Reports, 2019, 9, 10624.	1.6	27
35	Acute pancreatitis and vasoplegic shock associated with leptospirosis – a case report and review of the literature. BMC Infectious Diseases, 2019, 19, 395.	1.3	16
36	OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. Journal of Hepatology, 2019, 70, 1103-1113.	1.8	57

TOBIAS BOETTLER

#	Article	IF	CITATIONS
37	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	4.2	31
38	NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. Journal of Hepatology, 2019, 70, 351-360.	1.8	32
39	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	1.1	29
40	Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1228-1229.	1.9	0
41	Differential virusâ€specific <scp>CD</scp> 8 <sup>+</sup> Tâ€cell epitope repertoire in hepatitis C virus genotype 1 versus 4. Journal of Viral Hepatitis, 2018, 25, 779-790.	1.0	7
42	Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. Gastroenterology, 2018, 154, 798-800.	0.6	1
43	Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. Alimentary Pharmacology and Therapeutics, 2018, 47, 801-808.	1.9	19
44	HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses, 2018, 10, 645.	1.5	40
45	Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterology Journal, 2018, 6, 1380-1390.	1.6	24
46	Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications, 2018, 2, 1051-1063.	2.0	12
47	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. Hepatology, 2017, 66, 666-667.	3.6	7
48	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017, 58, 247-255.	2.0	159
49	Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterology, 2017, 17, 98.	0.8	18
50	Pancreatic Tissue Transplanted in TheraCyte <sup>â,,¢</sup> Encapsulation Devices Is Protected and Prevents Hyperglycemia in a Mouse Model of Immune-Mediated Diabetes. Cell Transplantation, 2016, 25, 609-614.	1.2	51
51	Procedural and shuntâ€related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS). Alimentary Pharmacology and Therapeutics, 2016, 44, 1051-1061.	1.9	47
52	Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections. Gastroenterology, 2016, 150, 696-706.e3.	0.6	62
53	A rare cause of upper GI bleeding in a critically ill patient. Gut, 2016, 65, 1438-1438.	6.1	1
54	Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis. Digestive Diseases, 2015, 33, 608-612.	0.8	5

TOBIAS BOETTLER

#	Article	IF	CITATIONS
55	An uncommon presentation of a common pathogen. Gut, 2015, 64, 1411-1411.	6.1	1
56	Exogenous OX40 Stimulation during Lymphocytic Choriomeningitis Virus Infection Impairs Follicular Th Cell Differentiation and Diverts CD4 T Cells into the Effector Lineage by Upregulating Blimp-1. Journal of Immunology, 2013, 191, 5026-5035.	0.4	33
57	The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. Journal of Autoimmunity, 2013, 44, 40-48.	3.0	31
58	IL-7 receptor  blockade, an off-switch for autoreactive T cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12270-12271.	3.3	5
59	OX40 Facilitates Control of a Persistent Virus Infection. PLoS Pathogens, 2012, 8, e1002913.	2.1	57
60	Virus Infections in Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007682.	2.9	93
61	TGF-β Blockade Does Not Improve Control of an Established Persistent Viral Infection. Viral Immunology, 2012, 25, 120523091504003.	0.6	26
62	Can an immune-regulatory vaccine prevent HIV infection?. Expert Review of Anti-Infective Therapy, 2012, 10, 299-305.	2.0	9
63	Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Review of Clinical Immunology, 2011, 7, 45-53.	1.3	38
64	Type 1 diabetes vaccine development: Animal models vs. humans. Hum Vaccin, 2011, 7, 19-26.	2.4	14
65	Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D. International Immunopharmacology, 2010, 10, 1491-1495.	1.7	28
66	Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology, 2008, 48, 1821-1833.	3.6	60
67	Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biological Chemistry, 2008, 389, 457-67.	1.2	37
68	Expression of the Interleukin-7 Receptor Alpha Chain (CD127) on Virus-Specific CD8 + T Cells Identifies Functionally and Phenotypically Defined Memory T Cells during Acute Resolving Hepatitis B Virus Infection. Journal of Virology, 2006, 80, 3532-3540.	1.5	177
69	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 7860-7867.	1.5	386